Stifel Nicolaus analyst Bradley Canino maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) on October 17 and set a price target of $25.00. The company’s shares closed yesterday at $7.08.
Canino covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Arvinas Holding Company, and ALX Oncology Holdings. According to TipRanks, Canino has an average return of -30.2% and a 21.18% success rate on recommended stocks.
Currently, the analyst consensus on Relay Therapeutics is a Moderate Buy with an average price target of $25.00, which is a 253.11% upside from current levels. In a report released on October 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $33.00 price target.
See the top stocks recommended by analysts >>
RLAY market cap is currently $912.3M and has a P/E ratio of -2.57.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RLAY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Relay Therapeutics (RLAY) Company Description:
Relay Therapeutics Inc is a precision medicines company focused on enhancing small molecule therapeutic discovery in targeted oncology. Its pipeline products include RLY-1971 and RLY-4008 and among others.
Read More on RLAY:
- Relay Therapeutics price target raised to $33 from $30 at H.C. Wainwright
- Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors
- Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
- JPMorgan biotech analysts hold an analyst/industry conference call
- Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
